ATE292801T1 - Verfahren zum screening von inhibitoren von asp2 - Google Patents
Verfahren zum screening von inhibitoren von asp2Info
- Publication number
- ATE292801T1 ATE292801T1 AT00969693T AT00969693T ATE292801T1 AT E292801 T1 ATE292801 T1 AT E292801T1 AT 00969693 T AT00969693 T AT 00969693T AT 00969693 T AT00969693 T AT 00969693T AT E292801 T1 ATE292801 T1 AT E292801T1
- Authority
- AT
- Austria
- Prior art keywords
- cleavage
- asp
- compounds
- substrate
- asp2
- Prior art date
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 title abstract 4
- 101710150192 Beta-secretase 1 Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000003776 cleavage reaction Methods 0.000 abstract 4
- 230000007017 scission Effects 0.000 abstract 4
- 239000000758 substrate Substances 0.000 abstract 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924957.5A GB9924957D0 (en) | 1999-10-21 | 1999-10-21 | Novel treatment |
| PCT/GB2000/004039 WO2001029563A1 (en) | 1999-10-21 | 2000-10-19 | Method of screening for inhibitors of asp2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292801T1 true ATE292801T1 (de) | 2005-04-15 |
Family
ID=10863153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00969693T ATE292801T1 (de) | 1999-10-21 | 2000-10-19 | Verfahren zum screening von inhibitoren von asp2 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050277165A1 (de) |
| EP (1) | EP1224469B1 (de) |
| JP (1) | JP2003512043A (de) |
| AT (1) | ATE292801T1 (de) |
| AU (1) | AU7934900A (de) |
| DE (1) | DE60019321T2 (de) |
| ES (1) | ES2240183T3 (de) |
| GB (1) | GB9924957D0 (de) |
| WO (1) | WO2001029563A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
| NZ510708A (en) | 1998-09-24 | 2003-12-19 | Upjohn Co | Alzheimer's disease and Asp1 and Asp2 cleaving APP site (beta secretase) |
| US6844148B1 (en) | 1998-09-24 | 2005-01-18 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| HK1044545A1 (zh) | 1999-02-10 | 2002-10-25 | Elan Pharmaceuticals, Inc. | 贝他分泌酶组合物及其方法 |
| US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| AU2001252958A1 (en) | 2000-03-23 | 2001-10-03 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| WO2003002122A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| AU2002359301B2 (en) * | 2001-10-23 | 2008-07-03 | Comentis, Inc. | Beta-secretase inhibitors and methods of use |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| EP2281824A1 (de) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen |
| AR083819A1 (es) | 2010-11-10 | 2013-03-27 | Genentech Inc | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL |
| EP2643299B1 (de) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridinsulfonamidderivate zur behandlung von neurodegenerativen erkrankungen oder zuständen |
| JP2013158281A (ja) * | 2012-02-03 | 2013-08-19 | Shionogi & Co Ltd | 新規ｂａｃｅ１活性測定方法 |
| EP3008037B1 (de) | 2013-06-12 | 2018-09-26 | Merck Patent GmbH | Hydroxyethylenderivate zur behandlung von arthrose |
| EP3221364B1 (de) | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen |
| JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187153A (en) * | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
| US4963654A (en) * | 1989-02-13 | 1990-10-16 | Taisho Pharmaceutical Co., Ltd. | Peptide serine protease inhibitor |
| US5292652A (en) * | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
| WO1995013084A1 (en) * | 1992-05-11 | 1995-05-18 | Miles Inc. | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
| JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| WO1998015828A1 (en) * | 1996-10-07 | 1998-04-16 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
| GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
| US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
| EP1194449B1 (de) * | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitoren des memapsin 2 und ihre verwendung |
-
1999
- 1999-10-21 GB GBGB9924957.5A patent/GB9924957D0/en not_active Ceased
-
2000
- 2000-10-19 JP JP2001532104A patent/JP2003512043A/ja not_active Withdrawn
- 2000-10-19 AU AU79349/00A patent/AU7934900A/en not_active Abandoned
- 2000-10-19 EP EP00969693A patent/EP1224469B1/de not_active Expired - Lifetime
- 2000-10-19 AT AT00969693T patent/ATE292801T1/de not_active IP Right Cessation
- 2000-10-19 ES ES00969693T patent/ES2240183T3/es not_active Expired - Lifetime
- 2000-10-19 DE DE60019321T patent/DE60019321T2/de not_active Expired - Fee Related
- 2000-10-19 WO PCT/GB2000/004039 patent/WO2001029563A1/en not_active Ceased
-
2003
- 2003-01-21 US US10/348,595 patent/US20050277165A1/en not_active Abandoned
-
2006
- 2006-07-14 US US11/486,738 patent/US20070021348A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003512043A (ja) | 2003-04-02 |
| EP1224469B1 (de) | 2005-04-06 |
| AU7934900A (en) | 2001-04-30 |
| ES2240183T3 (es) | 2005-10-16 |
| WO2001029563A1 (en) | 2001-04-26 |
| US20050277165A1 (en) | 2005-12-15 |
| US20070021348A1 (en) | 2007-01-25 |
| GB9924957D0 (en) | 1999-12-22 |
| EP1224469A1 (de) | 2002-07-24 |
| DE60019321T2 (de) | 2005-09-08 |
| DE60019321D1 (de) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| NO20061736L (no) | Krystallform av epotilon B | |
| DE69427869D1 (de) | Botulinumtoxine zur behandlung von hyperhydrosis | |
| DE59611411D1 (de) | Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE360442T1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE173620T1 (de) | Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs | |
| DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
| DE60018200D1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| DE60016405D1 (de) | Neurodegenerative-erkrankung verwandtes gen | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| DE60026644D1 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
| DE60015098D1 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| DE60329000D1 (de) | C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
| ATE322898T1 (de) | Inhibitoren von mycobakterien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |